Hepatotoxicity of chemotherapy

被引:284
作者
King, PD [1 ]
Perry, MC [1 ]
机构
[1] Univ Missouri, Dept Internal Med, Div Hematol Oncol, Ellis Fischel Canc Ctr, Columbia, MO 65203 USA
关键词
hepatotoxicity; chemotherapy; cancer therapy; liver function;
D O I
10.1634/theoncologist.6-2-162
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
After assessment of tumor histology, the next important factor to consider in the selection of a chemotherapy regime is organ function. Patients who are to receive chemotherapy require careful assessment of liver function prior to treatment to determine which drugs may not be appropriate, and which drug doses should be modified. Following therapy abnormalities of liver function tests may be due to the therapy rather than to progressive disease, and this distinction is of critical importance. Furthermore, not all abnormalities in liver function are due to the tumor or its treatment, and other processes, such as hepatitis, must be kept in mind. This article reviews the hepatic toxicity of chemotherapeutic agents, and suggests dose modifications based upon liver function abnormalities. Emphasis is placed on agents known to be hepatotoxic, and those agents with hepatic metabolism.
引用
收藏
页码:162 / 176
页数:15
相关论文
共 217 条
  • [91] Drug elimination in chronic liver diseases
    Huet, PM
    Villeneuve, JP
    Fenyves, D
    [J]. JOURNAL OF HEPATOLOGY, 1997, 26 : 63 - 72
  • [92] TAXANES - A NEW CLASS OF ANTITUMOR AGENTS
    HUIZING, MT
    MISSER, VHS
    PIETERS, RC
    HUININK, WWT
    VEENHOF, CHN
    VERMORKEN, JB
    PINEDO, HM
    BEIJNEN, JH
    [J]. CANCER INVESTIGATION, 1995, 13 (04) : 381 - 404
  • [93] HUTTER RVP, 1960, CANCER, V13, P288, DOI 10.1002/1097-0142(196003/04)13:2<288::AID-CNCR2820130213>3.0.CO
  • [94] 2-L
  • [95] Ishak KG, 1995, GASTROENTEROL CLIN N, V24, P759
  • [96] ETOPOSIDE (VP-16-213)
    ISSELL, BF
    CROOKE, ST
    [J]. CANCER TREATMENT REVIEWS, 1979, 6 (02) : 107 - 124
  • [97] JOENSUU H, 1986, CANCER, V58, P1437, DOI 10.1002/1097-0142(19861001)58:7<1437::AID-CNCR2820580710>3.0.CO
  • [98] 2-A
  • [99] JOHNSON DH, 1983, CANCER TREAT REP, V67, P1023
  • [100] PHASE I-II CLINICAL AND PHARMACOLOGICAL STUDIES OF HIGH-DOSE CYTOSINE-ARABINOSIDE IN REFRACTORY LEUKEMIA
    KANTARJIAN, HM
    ESTEY, EH
    PLUNKETT, W
    KEATING, MJ
    WALTERS, RS
    IACOBONI, S
    MCCREDIE, KB
    FREIREICH, EJ
    [J]. AMERICAN JOURNAL OF MEDICINE, 1986, 81 (03) : 387 - 394